Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CUV | Sydney | AUD | Delayed | |
CLVLY | OTC Markets | USD | Delayed | |
CLVLF | OTC Markets | USD | Delayed |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Neutral | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Sell | Strong Sell | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Homing Pigeon | 1M | Current | |||
Completed Patterns | |||||
Tri-Star Bearish | 5H | 5 | Feb 21, 2024 19:00 | ||
Tri-Star Bearish | 1H | 5 | Feb 21, 2024 20:00 | ||
Tri-Star Bearish | 15 | 5 | Feb 21, 2024 20:15 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Sydney | 14.36 | 14.35 | 14.36 | 84,624 | +1.27% | AUD | |||
OTC Markets | 9.080 | 0.000 | 0.000 | 1,176 | +0.55% | USD | |||
OTC Markets | 8.7800 | 0.0000 | 0.0000 | 0 | 0.00% | USD |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 174.70 | 174.70 | 170.95 | +3.05 | +1.78% | 9.80M | 11:07:13 | ||
Rolls-Royce Holdings | 425.20 | 426.20 | 411.40 | +3.20 | +0.76% | 4.38M | 11:07:04 | ||
Lloyds Banking | 51.84 | 52.54 | 51.57 | +0.17 | +0.33% | 45.44M | 11:07:25 | ||
Vodafone Group PLC | 70.110 | 70.303 | 69.740 | +0.690 | +0.99% | 8.85M | 11:07:06 | ||
BP | 494.86 | 497.40 | 493.30 | +2.06 | +0.42% | 4.93M | 11:06:56 | ||
Avacta Group | 47.80 | 48.94 | 47.33 | -1.20 | -2.45% | 1.18M | 11:07:14 | ||
HSBC | 624.50 | 627.50 | 618.00 | +9.50 | +1.54% | 4.05M | 11:06:36 | ||
Carnival | 1,223.5 | 1,236.5 | 1,216.0 | -13.0 | -1.05% | 203.94K | 11:07:02 | ||
Barclays | 183.62 | 184.14 | 182.82 | +2.10 | +1.16% | 6.97M | |||
AstraZeneca | 10,706.0 | 10,780.0 | 10,700.0 | -36.0 | -0.34% | 223.21K | 11:07:00 |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review